Compare UHG & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHG | ATYR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | 195 | 58 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 73.7M |
| IPO Year | N/A | N/A |
| Metric | UHG | ATYR |
|---|---|---|
| Price | $1.19 | $0.83 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 79.1K | ★ 968.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $0.64 |
| 52 Week High | $4.78 | $7.29 |
| Indicator | UHG | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 50.84 |
| Support Level | $1.15 | $0.68 |
| Resistance Level | $1.81 | $0.86 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 77.78 | 76.19 |
United Homes Group Inc designs, builds and sells homes in high growth markets, including South Carolina, North Carolina, and Georgia. UHG employs a land-light operating, with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).